<DOC>
	<DOCNO>NCT01106092</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety three formulation GSK Biologicals ' GSK2036874A vaccine compare Zilbrix™/Hib Poliorix™ vaccine administer concomitantly , administer single booster dose healthy poliovirus-primed toddler age 12-24 month .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Reactogenicity Booster Dose GSK2036874A Vaccine Healthy Toddlers</brief_title>
	<detailed_description>The study conduct partially double-blinded manner . The study double-blinded respect three GSK2036874A formulation group open-label respect Control Group .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female subject , include 12 24 month age time booster vaccination . Subjects receive three dos polio vaccine primary vaccination along routine vaccination indicate first year life . Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . Written inform consent obtain parent ( ) /Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination , plan administration active study period ( Visit 2 ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis and/or Haemophilus influenza type b disease . Previous booster vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B H. influenzae disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . History neurologic disorder seizure . History reaction hypersensitivity likely exacerbate component vaccine . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Child care . Occurrence follow adverse event previous administration diphtheriatetanuspertussis vaccine : encephalopathy unknown aetiology occur within seven day follow previous vaccination pertussiscontaining vaccine , fever &gt; = 40 °C within 48 hour vaccination due another identifiable cause , collapse shocklike state within 48 hour vaccination , convulsion without fever , occur within 3 day vaccination . Acute disease and/or fever time enrolment . Fever define temperature &gt; = 37.5°C oral , axillary tympanic setting , &gt; = 38.0°C rectal setting . Subjects minor illness without fever may , enrol discretion investigator . Other condition , opinion investigator , may potentially interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>